Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
09:10am, Thursday, 26'th Jun 2025
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
Cathie Wood Is Dumpster Diving Again With These 3 Stock Buys
11:50am, Wednesday, 25'th Jun 2025
Key Points in This Article: Cathie Wood's ARK Innovation ETF (ARKK) has seen a mixed performance over the past five years, reflecting her high-risk, high-reward focus on disruptive technologies to pro
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
07:13am, Monday, 23'rd Jun 2025
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumin
FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?
12:41pm, Friday, 20'th Jun 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Illumina (ILMN). But which of these two stocks offers v
Insiders Have Been Aggressively Buying These 5 Stocks
08:55am, Friday, 20'th Jun 2025
It's the insiders that know their company the best. And if they're willing to put their money where their mouths are, you may want to pay attention to why.
Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling
09:00am, Wednesday, 18'th Jun 2025
BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing r
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
04:01pm, Tuesday, 10'th Jun 2025
SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR)
Florida Cancer Specialists & Research Institute Launches Liquid Biopsy
10:05am, Monday, 09'th Jun 2025
Statewide Practice Continues to Enhance Genomic Testing to Advance Cancer Care, Improve Cure Rates and Enhance Patient Experience FORT MYERS, Fla., June 9, 2025 /PRNewswire/ -- Liquid biopsy, a blood
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
10:31am, Friday, 30'th May 2025
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
02:01pm, Thursday, 29'th May 2025
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina
Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
12:18am, Thursday, 29'th May 2025
Illumina, Inc. (NASDAQ:ILMN ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 2:30 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participant
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
09:16am, Wednesday, 28'th May 2025
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
09:15am, Wednesday, 28'th May 2025
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illum
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
09:51am, Tuesday, 20'th May 2025
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
11:47am, Monday, 19'th May 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina
